Related Experiment Videos
Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions
1Hertford College, Oxford University, England.
Journal of Clinical Pharmacology
|July 1, 1987
Summary
Bevantolol, a beta-1 adrenoceptor antagonist, effectively treats angina and hypertension. It uniquely reduces peripheral vascular resistance and lacks common side effects like cold extremities, suggesting alpha-adrenoceptor interaction.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Bevantolol is a beta-1 adrenoceptor antagonist used for angina and hypertension.
- Traditional beta-blockers can cause side effects like cold extremities and increased vascular resistance.
Purpose of the Study:
- To review new evidence on bevantolol's properties and mechanisms.
- To investigate bevantolol's interaction with alpha-adrenoceptors.
Main Methods:
- Review of published and unpublished evidence.
- Analysis of animal experiments and human investigations.
Main Results:
- Bevantolol shows efficacy comparable to other beta-blockers.
- Evidence supports bevantolol's interaction with alpha-adrenoceptors, including in the brain.
- Bevantolol reduces, rather than increases, peripheral vascular resistance and has few side effects.
Conclusions:
- Bevantolol's unique effects, including reduced peripheral vascular resistance and absence of cold extremities, are likely due to partial agonism at alpha-adrenoceptors.
- Bevantolol offers an effective treatment option for hypertension and angina with an improved side effect profile.